#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3678	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2456	445.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1864	1864	T	564	T	500	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3678	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2456	445.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1598	1598	C	525	C	459	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	448.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1863	1863	A	578	A	509	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	448.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2497	2497	C	573	C,T	501,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	448.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2571	2571	A	583	A	508	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3967	448.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3123	3123	C	509	C	422	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	27	596	folP	852	852	99.88	folP.l15.c4.ctg.1	1920	93.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1418	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3767	113.0	1	SNP	p	S91F	0	.	.	271	273	TCC	752	754	TCC	124;124;126	T,A;C;C	97,1;101;103	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1418	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3767	113.0	1	SNP	p	D95G	0	.	.	283	285	GAC	764	766	GAC	127;128;129	G;A;C	105;104;106	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1418	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3767	113.0	1	SNP	p	D95N	0	.	.	283	285	GAC	764	766	GAC	127;128;129	G;A;C	105;104;106	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	512	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1584	96.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	597	599	ACC	149;149;149	A,G;C;C	128,1;129;130	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	512	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1584	96.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	795	797	CAC	139;137;137	C;A;C	121;124;121	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	512	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1584	96.8	0	.	p	.	0	E117K	NONSYN	349	351	GAA	831	833	AAA	146;144;144	A;A;A	132;131;130	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	512	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1584	96.8	1	SNP	p	G45D	0	.	.	133	135	GGC	615	617	GGC	148;149;149	G;G,C;C	132;131,1;131	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	340	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1562	65.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1851	1853	ATC	126;125;127	A;T,A;C	109;106,1;108	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	2004	2006	GCA	116;115;115	G;C;A	102;102;100	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2487	2489	ATT	130;130;130	A;T;T	115;115;114	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	1	SNP	p	D86N	0	.	.	256	258	GAC	957	959	GAC	138;137;138	G;A;C,A	127;123;128,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	1	SNP	p	S87R	0	.	.	259	261	AGT	960	962	AGT	138;139;139	A;G;T	122;130;126	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	1	SNP	p	S87I	0	.	.	259	261	AGT	960	962	AGT	138;139;139	A;G;T	122;130;126	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	1	SNP	p	S87W	0	.	.	259	261	AGT	960	962	AGT	138;139;139	A;G;T	122;130;126	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	795	1134	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3532	96.0	1	SNP	p	S88P	0	.	.	262	264	TCC	963	965	TCC	138;138;138	T;C;C	127;122;129	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1156	parE	1986	1986	99.9	parE.l15.c17.ctg.1	2983	116.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1710	1712	GGC	161;161;157	G;G;C	138;137;137	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1342	1344	GCA	124;123;122	G;C;A	110;107;107	penA.22.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1345	1347	ATC	123;123;125	A;T;C	106;105;108	penA.22.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1357	1359	GTG	124;123;124	G;T;G	106;105;108	penA.22.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1357	1359	GTG	124;123;124	G;T;G	106;105;108	penA.22.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1861	1863	ACC	144;144;143	A;C;C	130;127;128	penA.22.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1915	1917	GCG	144;143;143	G,A;C;G	124,1;114;120	penA.22.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1915	1917	GCG	144;143;143	G,A;C;G	124,1;114;120	penA.22.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2038	2040	GGT	139;139;140	G;G;T,G	113;119;115,1	penA.22.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2047	2049	GGC	140;140;140	G,T;G,T;C	115,1;117,1;115	penA.22.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	954	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2699	105.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2065	2067	CCG	137;137;138	C;C;G	100;114;110	penA.22.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1290	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3341	115.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	682	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2144	95.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	702	702	C	118	C	99	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	632	porB1b	1047	1047	99.04	porB1b.l6.c17.ctg.1	1591	110.2	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	810	812	CAA	139;141;141	C;A;A	118;121;120	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	632	porB1b	1047	1047	99.04	porB1b.l6.c17.ctg.1	1591	110.2	0	.	p	.	0	E212G	NONSYN	634	636	GAA	1017	1019	GGT	122;122;122	G;G;T	109;109;111	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	632	porB1b	1047	1047	99.04	porB1b.l6.c17.ctg.1	1591	110.2	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1020	1022	GAT	121;120;120	G;A;T	109;107;107	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	632	porB1b	1047	1047	99.04	porB1b.l6.c17.ctg.1	1591	110.2	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1026	1028	GCT	120;120;120	G;C;T	104;105;107	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	632	porB1b	1047	1047	99.04	porB1b.l6.c17.ctg.1	1591	110.2	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1035	1037	ATG	119;120;120	A;T;G	105;105;106	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	632	porB1b	1047	1047	99.04	porB1b.l6.c17.ctg.1	1591	110.2	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1152	1154	AAG	116;116;115	A;A,C;G	99;99,1;97	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	632	porB1b	1047	1047	99.04	porB1b.l6.c17.ctg.1	1591	110.2	1	SNP	p	G120K	0	.	.	358	360	GGC	741	743	GGC	141;141;142	G;G;C	117;114;116	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2442	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5150	141.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2134	2136	CAT	140;140;139	C;A;T	125;122;124	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	396	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1263	94.0	1	SNP	p	V57M	0	.	.	169	171	GTG	662	664	GTG	162;162;163	G;T;G	137;139;139	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
